Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.33 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.33 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.33 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.33 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.33 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.33 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.33 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037491 | 1.00 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL18595259 | 1.00 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL17037490 | 1.00 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL16383055 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL16383069 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL16766054 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL25907745 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL21948079 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL21948078 | 0.93 | L3MBTL1 (0.34) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL19043993 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630495-B2 | Method for producing esters of homovanillic acid | SYMRISE AG (DE) | 2026-05-19 | — | — | US | disclosed |
| EP-4500182-A1 | PROGNOSTIC BIOMARKERS | The University of Liverpool (GB) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023180753-A1 | PROGNOSTIC BIOMARKERS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230167045-A1 | METHOD FOR PRODUCING ESTERS OF HOMOVANILLIC ACID | SYMRISE AG (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230054411-A1 | 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2023-02-16 | — | — | US | disclosed |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-07-14 | — | — | US | disclosed |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| EP-2574638-B1 | (Meth)acrylic-Modified Organopolysiloxane, Radiation-Curable Silicone Composition, Silicone Release Liner, and Making Methods | SHINETSU CHEMICAL CO (JP) | 2017-09-06 | — | — | EP | disclosed |
| US-20150225577-A1 | SILICONE MIST INHIBITOR | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20130085203-A1 | (METH)ACRYLIC-MODIFIED ORGANOPOLYSILOXANE, RADIATION-CURABLE SILICONE COMPOSITION, SILICONE RELEASE LINER, AND MAKING METHODS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8367212-B2 | an organopolysiloxane and an organopolysiloxane containing epoxy groups at the two terminals of the molecular chain; can be readily peeled from a pressure sensitive adhesive; release paper | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-2447329-A1 | Radiation curable silicone composition | Shin-Etsu Chemical Co., Ltd. (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20100255417-A1 | RADIATION-CURABLE SILICONE COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20080176086-A1 | ULTRAVIOLET-CURABLE SILICONE COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1947133-A1 | Ultraviolet-curable silicone composition | Shin-Etsu Chemical Co., Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085203-A1 | (METH)ACRYLIC-MODIFIED ORGANOPOLYSILOXANE, RADIATION-CURABLE SILICONE COMPOSITION, SILICONE RELEASE LINER, AND MAKING METHODS | MMAB, IDUA, MSR1 | ALDH1A1 1478/4885L3MBTL1 427/4885ATP1A1 4317/4885 |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | ALDH1A1 4227/4885L3MBTL1 3154/4885ATP1A1 3832/4885 |
| US-20230054411-A1 | 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 1156/4885L3MBTL1 4506/4885ATP1A1 267/4885 |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | ALDH1A1 2145/4885L3MBTL1 4730/4885ATP1A1 3476/4885 |
| US-20230167045-A1 | METHOD FOR PRODUCING ESTERS OF HOMOVANILLIC ACID | SLC6A6, SLC26A4, SLC6A2 | ALDH1A1 135/4885L3MBTL1 3934/4885ATP1A1 659/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | ALDH1A1 1798/4885L3MBTL1 605/4885ATP1A1 4335/4885 |
| US-20220220103-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | ALDH1A1 4227/4885L3MBTL1 3154/4885ATP1A1 3832/4885 |
| US-20230048132-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | ALDH1A1 4227/4885L3MBTL1 3154/4885ATP1A1 3832/4885 |
| US-12630495-B2 | Method for producing esters of homovanillic acid | ADH1C, ADH1A, SLC6A6 | ALDH1A1 86/4885L3MBTL1 2937/4885ATP1A1 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.